Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budigalimab, Revdofilimab, and Giloralimab in HNSCC
NCT03818542Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2020
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of budigalimab, revdofilimab and giloralimab in head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Changes in Gene Expression. Started Jan 2020; status: terminated.
02
Drugs
budigalimabrevdofilimabgiloralimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03818542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818542.